查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615420

基因生物標記市場：按產品類型、適應症和最終用戶分類 - 2025-2030 年全球預測

Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

基因生物標記市場2023年估值為44億美元，預計到2024年將達到46.7億美元，複合年成長率為6.67%，預計到2030年將達到69.2億美元。

基因生物標記是用於測量和評估生物過程和反應的 DNA/RNA 特徵，對於透過實現個人化治療方法來推進精準醫學至關重要。慢性病盛行率的不斷上升、精準醫學研究的激增以及向個人化醫療解決方案的轉變推動了對基因生物標記的需求。這些生物標記在個人化醫療、疾病診斷、藥物開發和風險評估方面有著重要的應用。最終用途包括腫瘤學、心臟代謝疾病、神經病學和感染疾病，提供量身定做的健康解決方案，以改善患者的治療效果並降低醫療成本。市場成長受到次世代定序儀等技術進步、個人化醫療需求不斷成長以及製藥和生物技術公司投資增加的影響。各國政府也透過戰略資助和法律規範支持來促進研究和發展。然而，基因組技術的高成本、有關遺傳資料隱私的倫理問題以及生物標記檢驗的複雜性等挑戰可能會阻礙市場成長。基因組學的不斷發展需要強大的計算工具和方法來分析複雜的資料集，這是創新的關鍵領域。精準腫瘤學透過基因生物標記指導最佳的癌症治療，有可能帶來顯著的益處。有開發具有成本效益的解決方案和即時檢測創新的機會，並且促進生物技術公司和學術機構之間的合作可以加快臨床實施。競爭格局顯示出不斷增加的合併和策略聯盟趨勢，以擴大技術組合和市場覆蓋範圍。專注於技術整合和解決資料隱私問題可以為成功鋪平道路。在創新、監管變化和基因組學知識庫進步的推動下，市場動態不斷變化且快速發展，為旨在生物製藥行業長期永續性和競爭優勢的投資提供了強大的機會。

主要市場統計
基準年[2023] 44億美元
預測年份 [2024] 46.7億美元
預測年份 [2030] 69.2億美元
複合年成長率（%） 6.67%

市場動態：揭示快速發展的基因生物標記市場的關鍵市場洞察

供需的動態交互作用正在改變基因生物標記市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 擴大基因生物標記在慢性病早期檢測與診斷的應用
    • 政府和監管調查協助
    • 擴大基因生物標記在個人化醫療中的使用
  • 市場限制因素
    • 與基因生物標記開發相關的高成本和技術問題
  • 市場機會
    • 將人工智慧和機器學習與基因組研究結合
    • 人們對先進的非侵入性基因生物標記開發越來越感興趣
  • 市場挑戰
    • 關於使用基因生物標記的倫理和法律問題

波特的五力：駕馭基因生物標記市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基因生物標記市場的外部影響

外部宏觀環境因素在塑造基因生物標記市場的動態表現方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解基因生物標記市場的競爭狀況

對基因生物標記市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣基因生物標記市場供應商的績效評估

FPNV定位矩陣是評估基因生物標記市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製基因生物標記市場的成功之路

基因生物標記市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 更多地使用基因生物標記來早期檢測和診斷慢性疾病
      • 政府和監管部門對基因生物標記研究的支持
      • 擴大基因生物標記在個人化醫療的應用
    • 抑制因素
      • 與開發基因生物標記相關的高成本和技術問題
    • 機會
      • 整合人工智慧、機器學習和基因組研究
      • 人們對開發先進的非侵入性基因生物標記越來越感興趣
    • 任務
      • 關於使用基因生物標記的倫理和法律問題
  • 市場區隔分析
    • 類型：擴大預後生物標記在藥物研究中的使用
    • 最終使用者：擴大基因生物標記在診斷中心的應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章基因生物標記市場：依產品

  • 消耗品
  • 服務
  • 軟體

第7章基因生物標記市場：依類型

  • 預測性生物標記
  • 預後生物標記

第8章基因生物標記市場：依疾病指示

  • 心血管疾病
  • 神經系統疾病
  • 腫瘤學
  • 腎臟疾病

第 9 章基因生物標記市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 調查機構

第10章美洲基因生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區基因生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的基因生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Bio-Rad 推出創新的多重數位 PCR 檢測以增強乳癌監測
    • 使用 Biofidelity 的 ASPYRE-Lung RUO 試劑增強快速基因生物標記分析簡介
    • Illumina 在腫瘤學領域取得突破 TruSight Oncology 500 ctDNA v2 為固態腫瘤基因組分析提供支持
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocrates Life Sciences AG
  • Biostarks Laboratories SA
  • Bruker Corporation
  • CD Genomics
  • Charles River Laboratories, Inc.
  • DH Life Sciences, LLC.
  • Elo Health, Inc.
  • Eurofins Scientific corporation
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc.
  • Merck KGaA
  • Myriad Genetics, Inc
  • Owkin, Inc
  • Thermo Fisher Scientific company
Product Code: MRR-CB04E0565332

The Genomic Biomarker Market was valued at USD 4.40 billion in 2023, expected to reach USD 4.67 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 6.92 billion by 2030.

Genomic biomarkers are DNA/RNA signatures used to measure and evaluate biological processes or responses, pivotal in driving precision medicine advances by enabling individualized therapeutic approaches. The need for genomic biomarkers is driven by the increasing prevalence of chronic diseases, a surge in precision medicine research, and the shifts towards personalized healthcare solutions. These biomarkers find significant applications in personalized medicine, disease diagnosis, drug discovery and development, and risk assessment. Their end-use spans across oncology, cardio-metabolic disorders, neurology, and infectious diseases, providing tailored health solutions to improve patient outcomes and reduce healthcare costs. Market growth is influenced by technological advancements like next-gen sequencing, rising demand for personalized medicine, and increased investments by pharmaceutical and biotech companies. Governments are also fostering R&D through strategic funding and supportive regulatory frameworks. However, challenges such as high costs of genomic technologies, ethical concerns related to genetic data privacy, and the complexity of biomarker validation may hinder market growth. The constant evolution of genomics necessitates robust computational tools and methodologies to analyze complex datasets, representing a significant innovation area. Precision oncology can benefit greatly, where genomic biomarkers guide optimal cancer therapies. Opportunities lie in developing cost-effective solutions and point-of-care testing innovations, encouraging collaborations between biotech firms and academic institutions to expedite clinical implementations. The competitive landscape shows an increasing trend of mergers and strategic alliances to broaden technology portfolios and market reach. Focusing on technology integration and addressing data privacy concerns can forge a successful path forward. The nature of the genomic biomarker market is dynamic and rapidly evolving, driven by innovation, regulatory changes, and the progressing knowledge base in genomics, providing a potent platform for investments aiming at long-term sustainability and competitive advantage in the biopharmaceutical industry.

KEY MARKET STATISTICS
Base Year [2023] USD 4.40 billion
Estimated Year [2024] USD 4.67 billion
Forecast Year [2030] USD 6.92 billion
CAGR (%) 6.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genomic Biomarker Market

The Genomic Biomarker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
    • Governments and regulatory support for genomic biomarker research
    • Growing applications of genomic biomarkers in personalized medicine
  • Market Restraints
    • High cost and technical issues associated with developing genomic biomarkers
  • Market Opportunities
    • Integration of AI and machine learning with genomic studies
    • Growing interest in developing advanced noninvasive genomic biomarkers
  • Market Challenges
    • Ethical and legal concerns regarding the use of genomic biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Genomic Biomarker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genomic Biomarker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genomic Biomarker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genomic Biomarker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genomic Biomarker Market

A detailed market share analysis in the Genomic Biomarker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genomic Biomarker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genomic Biomarker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genomic Biomarker Market

A strategic analysis of the Genomic Biomarker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage

This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Services, and Software.
  • Based on Type, market is studied across Predictive Biomarkers and Prognostic Biomarkers.
  • Based on Disease Indication, market is studied across Cardiovascular Diseases, Neurological Diseases, Oncology, and Renal Disorders.
  • Based on End-User, market is studied across Diagnostic Centers, Hospitals, and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
      • 5.1.1.2. Governments and regulatory support for genomic biomarker research
      • 5.1.1.3. Growing applications of genomic biomarkers in personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and technical issues associated with developing genomic biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of AI and machine learning with genomic studies
      • 5.1.3.2. Growing interest in developing advanced noninvasive genomic biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and legal concerns regarding the use of genomic biomarkers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Proliferating use of prognostic biomarkers in pharmaceutical research
    • 5.2.2. End-user: Expanding application of genomic biomarkers in diagnostic centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genomic Biomarker Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Software

7. Genomic Biomarker Market, by Type

  • 7.1. Introduction
  • 7.2. Predictive Biomarkers
  • 7.3. Prognostic Biomarkers

8. Genomic Biomarker Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Neurological Diseases
  • 8.4. Oncology
  • 8.5. Renal Disorders

9. Genomic Biomarker Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals
  • 9.4. Research Institutions

10. Americas Genomic Biomarker Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Genomic Biomarker Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Genomic Biomarker Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
    • 13.3.2. Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
    • 13.3.3. Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. APIS Assay Technologies Limited
  • 4. Augurex Life Sciences Corp
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Bio-Techne Corporation
  • 7. Biocrates Life Sciences AG
  • 8. Biostarks Laboratories SA
  • 9. Bruker Corporation
  • 10. CD Genomics
  • 11. Charles River Laboratories, Inc.
  • 12. DH Life Sciences, LLC.
  • 13. Elo Health, Inc.
  • 14. Eurofins Scientific corporation
  • 15. F. Hoffmann-La Roche Ltd
  • 16. Illumina Inc.
  • 17. Merck KGaA
  • 18. Myriad Genetics, Inc
  • 19. Owkin, Inc
  • 20. Thermo Fisher Scientific company

LIST OF FIGURES

  • FIGURE 1. GENOMIC BIOMARKER MARKET RESEARCH PROCESS
  • FIGURE 2. GENOMIC BIOMARKER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENOMIC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENOMIC BIOMARKER MARKET DYNAMICS
  • TABLE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023